Ashley Jenne, managing director, strategy and business development at Evernorth, discusses the evolution of the PBM’s digital health formulary.
Formulary Watch
Latest News
All News
Advertisement
Regulators used a re-analysis of data from an observational case-control study of Tdap vaccine effectiveness to show that Boostrix given in the third-trimester prevented pertussis among infants.
This approval for Oxlumo adds lowering plasma oxalate levels for patients with primary hyperoxaluria type 1, a rare and life-threatening metabolic disease.
In 2023, Capital Blue Cross members will be able to use their insurance cards at Mark Cuban Cost Plus Drugs. This is the first time the online pharmacy will accept insurance.
EmpiRx Health CEO Karthik Ganesh discusses how the PBM was able to decrease mental health drug spending at a time when utilization is increasing.
The FDA had indicated that it would not issue an emergency use authorization without additional data for peginterferon lambda to treat patients with mild-to-moderate COVID-19.
UnitedHealthcare is moving more drugs to the lower-cost tiers in its Medicare Advantage plans. Other plans will have $0 copays and insulin at a $25 copay.
The FDA is expected to make a decision on approval in this patient population in the first half of 2023.
Medicare and Medicaid spent more than $18 billion on drugs without verified clinical benefit.
The online pharmacy has added 12 new products and lowered the costs of 39 medications.
Advertisement
SIGA indicated that $5.1 million of oral Tpoxx is targeted for delivery in 2022.
All plans have $0 copay options for select medications purchased through preferred home delivery.
In one lot, a bottle containing clopidogrel was mislabeled as atenolol. This lot was sold to AmerisourceBergen and McKesson.
Trogarzo was approved with a new method of administration designed to make maintenance dosing easier for patients and healthcare providers.
Humana’s 2023 Medicare pharmacy benefits updates include $0 copays, simplified access to prescriptions and Veteran’s focused-plans that add pharmacy benefits.
If approved, valoctocogene roxaparvovec would be the first commercially-available gene therapy in the United States for the treatment of severe hemophilia A.
The retailer indicated that Express Scripts’ drug pricing model is unstainable for Kroger and its customers.
Taiho’s Lytgobi is approved to treat advanced or metastatic advanced bile duct cancer in patients with FGFR2 gene fusions.
A new formulary design will be offered on the Value Script and Value Plus plans; it will contain medications used to treat diabetes and will cost only $11 per 30-day supply.
Now with the brand name Relyvrio, the new therapy should be available within four to six weeks. It will have a wholesale acquisition cost of $158,000 per year.
Dupixent is the first treatment approved to treat prurigo nodularis, a chronic skin disorder characterized by the presence of hard, itchy nodules.
Dark red, brown and black particulates were seen inside of one vial. Acyclovir is used to treat genital herpes and shingles.
Jing Yang from IQVIA discusses how national payers are using formulary exclusions for oncology therapeutics.
Vegzelma is Celltrion’s third oncology biosimilar to be approved by the FDA.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, for a decision on leniolisib as a treatment for APDS, a rare primary immunodeficiency.
In 2021, patients in the United States received 6.4 billion prescriptions, 91% of which were generic and biosimilar medicines.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CMS sets the 2027 Part D bid amount at $296.05, will end premium subsidy program
2
PSG: Specialty drug spending predicted to increase 32% by 2028
3
Investigational non-opioid LTG-001 reduced acute pain in phase 2b trial
4
FSGS Subtypes and Genetics: Why Classification Still Falls Short
5